Physician profile
Gordon Lee
NPI 1578561684
$3,939.36
in general payments reported to CMS, 2019-2025
24 companies · $716 in 2025
The $716 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $547 · 2022: $902 · 2023: $959 · 2024: $817 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,490.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $904.89 | 2021-2025 | |
| Novo Nordisk INC | $498.01 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $365.34 | 2021-2025 | Otezla, Repatha, Evenity |
| Otsuka America Pharmaceutical, INC. | $322.07 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $242.87 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205.24 | 2022-2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $175.13 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $164.90 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.49 | 2021-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $136.97 | 2022-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.02 | 2021-2025 | Jardiance |
| Dexcom, INC. | $110.67 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $94.67 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $84.09 | 2021-2025 | Capvaxive, Vaxneuvance, Verquvo |
| Pfizer INC. | $79.82 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $66.33 | 2021-2023 | Trintellix |
| Phathom Pharmaceuticals, INC. | $42.32 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $35.51 | 2021 | |
| Amarin Pharma, INC. | $29.92 | 2021-2022 | |
| Biogen, INC. | $27.62 | 2021-2022 | |
| Electromed, INC. | $25.79 | 2025 | Smartvest |
| Axsome Therapeutics, INC. | $17.09 | 2025 | Auvelity |
| Mylan Specialty L.P. | $15.82 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.